https://mindmedicinelaw.com/briefing/mdma-assisted-therapy-nears-potential-fda-approval-in-the-us-20261023-53220The Psychedelic Journalen2026-10-23T22:04:21.564040+00:00MDMA-Assisted Therapy Nears Potential FDA Approval in the USmdma-assisted therapy, fda approval, psychedelic regulation, clinical trials, dea rescheduling, ptsd treatment, risk mitigation, health policy, lykos therapeutics, psychedelic medicinehttps://mindmedicinelaw.com/briefing/oregon-state-university-trials-psychedelic-therapy-for-end-of-life-distress-20261023-53046The Psychedelic Journalen2026-10-23T15:06:10.804697+00:00Oregon State University Trials Psychedelic Therapy for End-of-Life Distresspsychedelic-assisted therapy, oregon state university, cancer palliative care, clinical trial, end-of-life distress, psilocybin, oncology, fda regulation, insurance coverage, mental healthhttps://mindmedicinelaw.com/briefing/novel-benzodiazepines-and-severe-outcomes-in-nsw-surveillance-study-findings-20261022-53297The Psychedelic Journalen2026-10-24T15:06:05.353845+00:00Novel Benzodiazepines and Severe Outcomes in NSW: Surveillance Study Findingsnovel benzodiazepines, bromazolam, public health surveillance, drug policy australia, clinical toxicology, harm reduction, polysubstance use, risk ratio methodology, nsw drug trendshttps://mindmedicinelaw.com/briefing/neural-complexity-metrics-implications-for-psychedelic-brain-research-20261022-53312The Psychedelic Journalen2026-10-24T15:05:53.580596+00:00Neural Complexity Metrics: Implications for Psychedelic Brain Researchneural complexity, brain network analysis, psychedelic research, observational metrics, perturbational metrics, clinical trial design, consciousness, small-world networks, mechanistic studieshttps://mindmedicinelaw.com/briefing/psychedelic-use-outside-clinics-epidemiology-and-policy-gaps-20261022-53278The Psychedelic Journalen2026-10-24T15:05:41.764161+00:00Psychedelic Use Outside Clinics: Epidemiology and Policy Gapspsychedelic epidemiology, non-clinical use, public health surveillance, harm reduction, policy gaps, community experiences, adverse effects, population-level data, psychedelic risks, drug policyhttps://mindmedicinelaw.com/briefing/microglial-mitochondrial-dysfunction-and-depression-implications-for-psychedelic-20261022-52981The Psychedelic Journalen2026-10-23T15:07:27.917345+00:00Microglial Mitochondrial Dysfunction and Depression: Implications for Psychedelic Researchmicroglia, mitochondrial dysfunction, depression pathogenesis, neuroinflammation, psychedelic research, clinical trials, neuroimmune modulation, biomarkers, major depressive disorderhttps://mindmedicinelaw.com/briefing/subanesthetic-ketamine-for-opioid-refractory-cancer-pain-clinical-evidence-and-p-20261022-52980The Psychedelic Journalen2026-10-23T15:06:55.637847+00:00Subanesthetic Ketamine for Opioid-Refractory Cancer Pain: Clinical Evidence and Policy Outlooksubanesthetic ketamine, opioid-refractory cancer pain, analgesia, opioid-sparing, clinical trials, nmda receptor antagonists, adverse effects, palliative care, policy implications, pain managementhttps://mindmedicinelaw.com/briefing/lsd-extends-lifespan-in-c-elegans-mechanisms-and-implications-20261022-52930The Psychedelic Journalen2026-10-23T15:06:36.903152+00:00LSD Extends Lifespan in C. elegans: Mechanisms and Implicationslsd, c. elegans, serotonergic pathways, aging research, lifespan extension, nutrient-sensing, preclinical study, psychedelic science, gpcr signalinghttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-for-ptsd-us-evidence-review-2010-2025-20261021-53281The Psychedelic Journalen2026-10-24T15:05:02.988848+00:00MDMA-Assisted Therapy for PTSD: US Evidence Review 2010–2025mdma-assisted therapy, ptsd, integrative review, clinical trials, evidence certainty, grade system, research sponsorship, adverse events, cochrane review, regulatory policyhttps://mindmedicinelaw.com/briefing/pediatric-perioperative-esketamine-dose-dependent-effects-and-unresolved-safety--20261021-52985The Psychedelic Journalen2026-10-23T15:07:44.751681+00:00Pediatric Perioperative Esketamine: Dose-Dependent Effects and Unresolved Safety Boundariesesketamine, pediatric anesthesia, emergence delirium, dose-dependent effects, perioperative care, clinical trials, safety boundaries, pharmacokinetics, endpoint-specific outcomeshttps://mindmedicinelaw.com/briefing/esketamine-ect-combination-in-adolescent-depression-interim-trial-insights-20261021-52983The Psychedelic Journalen2026-10-23T15:05:50.517684+00:00Esketamine-ECT Combination in Adolescent Depression: Interim Trial Insightsesketamine, electroconvulsive therapy, adolescent depression, suicidal ideation, randomized controlled trial, cognitive safety, psychiatric protocols, regulatory policy, major depressive disorderhttps://mindmedicinelaw.com/briefing/ketset-trial-psychedelic-vs-biomedical-framing-of-ketamine-in-sweden-20261020-53315The Psychedelic Journalen2026-10-24T15:04:50.060365+00:00KetSet Trial: Psychedelic vs Biomedical Framing of Ketamine in Swedenketamine, treatment-resistant depression, psychedelic framing, biomedical framing, clinical trial, subjective experience, set and setting, health economics, Sweden, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/psychedelic-like-vr-for-ocd-feasibility-trial-in-germany-and-italy-20261019-52970The Psychedelic Journalen2026-10-23T15:07:12.342590+00:00Psychedelic-Like VR for OCD: Feasibility Trial in Germany and Italyvirtual reality, psychedelic simulation, obsessive-compulsive disorder, clinical trial, digital therapeutics, psychological flexibility, feasibility study, mental health policyhttps://mindmedicinelaw.com/briefing/psychedelics-delay-neurovascular-coupling-implications-for-fmri-research-20261016-53291The Psychedelic Journalen2026-10-24T15:05:28.999613+00:00Psychedelics Delay Neurovascular Coupling: Implications for fMRI Researchpsychedelics, neurovascular coupling, fMRI, LSD, DMT, serotonin receptors, clinical trial design, regulatory science, hemodynamic delay, neuroimaging analysishttps://mindmedicinelaw.com/briefing/eeg-study-reveals-context-dependent-alpha-band-effects-of-psilocybin-20261016-53302The Psychedelic Journalen2026-10-24T15:05:15.499540+00:00EEG Study Reveals Context-Dependent Alpha-Band Effects of Psilocybinpsilocybin, eeg, alpha-band connectivity, context effects, clinical trial design, set and setting, neural mechanisms, sensory input, psychedelic neuroscience